The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study

This pre-specified analysis (n=1058) found patients treated with IV ferric carboxymaltose had significantly greater improvements in health status starting at week 4, & continuing up to week 24, compared with placebo, with a subsequent attenuation of treatment benefit by week 52.

European Heart Journal